Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iseganan for Prevention of Ventilator-Associated Pneumonia
NCT00118781Phase 3Terminated
- Sponsor
- Intrabiotics Pharmaceuticals
- Start
- Sep 2003
- Modality
- Recombinant Proteins and Enzymes, Antimicrobial Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing Iseganan with Placebo (2 arms). Primary endpoint: Safety and efficacy of iseganan. Started Sep 2003; status: terminated.
02
Drugs
iseganan
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT00118781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118781.